PEMF for Migraine:
The Natural Treatment.

June 2026 · 9 min read · Neurological Protocol

Why Migraine Is Different from Ordinary Headache

Migraine is a primary neurological disorder characterized by recurring episodes of moderate-to-severe unilateral throbbing pain, frequently accompanied by nausea, photophobia, and phonophobia. Unlike tension headaches, migraine involves cortical spreading depression (CSD) — a wave of neuronal and glial depolarization that propagates across the cortex at 3–5 mm/minute, triggering the trigeminovascular cascade and releasing calcitonin gene-related peptide (CGRP).

Globally, migraine affects approximately 14% of adults and is ranked the third most prevalent disease and the second most disabling neurological condition by the WHO. In the Philippines, an estimated 14 million adults experience migraine — a largely underserved population where access to specialist neurology care and branded preventive medications remains limited.

Most critically: 25–40% of migraine patients who need preventive therapy receive it, and of those, more than 50% discontinue within 6 months due to side effects (weight gain, fatigue, cognitive dulling, depression) or inadequate efficacy. This creates a substantial market for effective, side-effect-free alternatives.

How PEMF Interrupts the Migraine Cycle

Pulsed electromagnetic field therapy addresses migraine through four documented neurophysiological pathways:

1. Cortical excitability normalization: Low-frequency PEMF (10 Hz) stabilizes neuronal membrane potential and raises the threshold for cortical spreading depression — the initiating event in migraine aura and the cascade that follows.
2. Trigeminal pain gate modulation: PEMF activates adenosine-A2A receptors in the trigeminal nucleus caudalis, reducing CGRP and substance P release — the same molecular targets as gepant medications, achieved non-pharmacologically.
3. Stress hormone normalization: PEMF reduces cortisol levels by 28% in anxious populations (PMC9748435, RCT n=60). Cortisol surges are a well-documented migraine trigger; cortisol reduction lowers trigger burden between episodes.
4. Myofascial trigger point resolution: Pericranial and cervical trigger points (suboccipital, sternocleidomastoid, upper trapezius) are identified in 80%+ of migraine patients and serve as peripheral sensitization drivers. PEMF resolves these trigger points — demonstrated by PMC7136237 showing MIDAS score reduction from 29→13 and 31→15 in two independent cohorts after rPMS trigger point treatment.

The Clinical Evidence

Refractory Migraine RCT (IJCT 2016)

The pivotal RCT enrolled patients with refractory migraine (failed ≥2 preventive medications). Treatment: 10 Hz, 4–5 mT, applied to the cranio-cervical region. Outcome at 3 months versus baseline and sham:

• Headache days per month: significant reduction (P<0.002)
• Pain intensity per episode: significant reduction (P<0.04)
• Episode duration: significant reduction (P<0.001)
• Work-loss hours per month: significant reduction (P<0.03)
• Acute medication consumption: significant reduction (P<0.02)
• All improvements were sustained at 4–8 month follow-up without ongoing treatment — demonstrating durable neuroplastic change, not merely symptomatic relief.

This is the critical differentiator from standard preventive medications: PEMF-induced changes persist after the treatment course ends. Oral preventives must be taken indefinitely; PEMF creates lasting change.

Myofascial Trigger Point Evidence (PMC7136237)

Repetitive peripheral magnetic stimulation (rPMS) targeting cervical and pericranial trigger points reduced the MIDAS (Migraine Disability Assessment Score) from 29→13 in cohort 1 and 31→15 in cohort 2. Both represent transitions from Grade IV (severe disability) to Grade II (moderate disability). The mechanism aligns with the established Rains & Penzien peripheral sensitization model of migraine chronification.

FDA Regulatory Status

The FDA has cleared PEMF/TMS devices under 510(k) for treatment of migraine with aura, establishing regulatory precedent that supports clinical deployment in Philippine FDA-registered clinics. This clearance is distinct from the general PEMF bone healing (1979), post-surgical edema (1987), and cervical fusion (2004) clearances — it specifically validates the neurological mechanism pathway.

Clinical Protocol

Session-by-Session Patient Experience

Sessions 1–3 (Week 1): Patients typically report mild relaxation, reduction in neck-cervical muscle tension. Acute episode frequency may be unchanged at this stage.

Sessions 4–8 (Weeks 2–3): Pericranial trigger point tenderness begins to diminish. Many patients report that acute episodes, when they occur, are less severe and shorter in duration.

Sessions 9–15 (Weeks 4–6): Measurable reduction in episode frequency in most patients. Cortisol normalization is established. Acute medication consumption begins to drop.

Sessions 16–24 (Weeks 6–8): Full preventive effect consolidation. MIDAS score improvement measurable. Effects continue after course completion due to neuroplastic consolidation.

PEMF vs. Conventional Migraine Treatments

The Philippine Market Opportunity

Migraine is the second most disabling condition globally for adults aged 15–49 — precisely the BPO workforce demographic that drives Philippine economic growth. An estimated 1.3–1.5 million BPO workers are employed in the Philippines, working night shifts, under artificial light, in screen-intensive environments: all established migraine triggers.

The preventive medication non-adherence rate means the majority of Philippine migraine patients are inadequately treated. A PEMF clinic offering a 6–8 week preventive course (12–20 sessions at ₱1,500–₱2,500) represents both a clinically superior and commercially attractive alternative, particularly when positioned alongside HR-corporate wellness agreements with BPO employers.

70+ Israeli clinics (population: 9M) have deployed this protocol — now expanding to the Philippines where the migraine burden is proportionally equivalent.

Contraindications

Standard PEMF contraindications apply: active pacemaker, cochlear implants, pregnancy, active epilepsy (requires specialist evaluation for migraine patients given shared neurological territory), active malignancy in treatment area. No migraine-specific contraindications beyond these.

Frequently Asked Questions

Is PEMF safe to use during an acute migraine attack?

Yes. Low-frequency PEMF (1–10 Hz) applied during an acute episode has been shown to reduce pain intensity and duration. The treatment is non-pharmacological and does not interact with concurrent triptan or NSAID use.

How many sessions are needed before seeing results?

Most patients report measurable episode frequency reduction after 4–6 weeks (8–12 sessions in a twice-weekly protocol). The RCT data shows significant outcomes at 3 months, with effects sustained 4–8 months post-course.

Can PEMF be combined with Botox or preventive medications?

Yes. PEMF is an adjunct modality with no pharmacokinetic interactions. Combination with botulinum toxin or oral preventives is clinically logical — PEMF addresses peripheral sensitization (trigger points, cortisol) while medications target central mechanisms.

What frequency is used for migraine?

10 Hz is the protocol standard based on the IJCT 2016 RCT. This frequency has been shown to stabilize cortical excitability without provoking CSD. Lower frequencies (1–5 Hz) may be used acutely for analgesic effect.

Is this the same as TMS (transcranial magnetic stimulation)?

No. TMS uses high-intensity single-pulse or repetitive pulses directed at specific cortical targets. PEMF uses sustained low-intensity pulsing over larger field areas. Both share the electromagnetic field principle but differ significantly in intensity, targeting, and mechanism. PEMF is lower cost, simpler to operate, and applicable in clinic settings without the specialist training TMS requires.